CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Insulin Aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00461331
NCT00461331Phase 4Completed
CompareCT.gov

A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps

Tulane University Health Sciences Center·interventional·Posted Apr 18, 2007·Updated Jan 8, 2021

In Brief

A Phase 4 clinical trial evaluating Insulin Aspart and Insulin Lispro for Type 1 Diabetes Mellitus. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of the study is to compare the glycemic control between insulins aspart and lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes using an insulin pump.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2007
Enrollment StartOct 1, 2004
Primary CompletionJun 1, 2007
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 19.2 years ago

Interventions

Insulin Aspartdrug

Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.

Insulin Lisprodrug

Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.